Prelude Therapeutics Inc

Ownership Transactions Reported by 18 Insiders

Symbol
PRLD on Nasdaq
Industry
Pharmaceutical Preparations
Location
175 Innovation Boulevard, Wilmington, DE

Insiders trading volume in the past year

Prelude Therapeutics Inc executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Orbimed Advisors Llc Director, 10%+ Owner $38.2M May 22, 2023
Krishna Vaddi CEO, Director $1.87M +$699K +59.9% Mar 25, 2025
Andrew Combs Chief Chemistry Officer $332K +$155K +87.1% Mar 25, 2025
Laurent Chardonnet Chief Financial Officer $159K Mar 1, 2024
Jane Huang President, CMO $154K Oct 4, 2025
Bryant D. Lim CLO, CFO, Corp Sec. $24.8K +$22.6K +1042% Feb 4, 2025
Christopher Pierce EVP and Chief of Business Oper $14.1K Sep 2, 2021
Deborah Morosini EVP, Chief of Clinical Affairs $1.67K Feb 15, 2022
Victor Sandor Director Jun 12, 2025
Paul C. Scherer Director Jun 12, 2025
David J. Mauro Chief Medical Officer Oct 5, 2021
Peggy Scherle Chief Scientific Officer Feb 4, 2025
Mardi Dier Director Jun 12, 2025
Martin Babler Director Jun 12, 2025
Brian Piper Chief Financial Officer Aug 25, 2021
Paul A. Friedman Director Jun 12, 2025
Baker Bros. Advisors Lp Director, 10%+ Owner Jun 12, 2025
David P. Bonita Director, 10%+ Owner Jun 12, 2025

Recent Insider Transactions by Companies or Individuals for Prelude Therapeutics Inc

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.